Two sickle cell disease therapies won US Food and Drug Administration approval on 8 December but bluebird bio inc.’s gene therapy Lyfgenia (lovotibeglogene autotemcel, lovo-cel) stumbled out of the gate with higher pricing, a black box warning and no priority review voucher, while Vertex Pharmaceuticals Incorporated/CRISPR Therapeutics AG may have a relatively easier path with Casgevy (exagamglogene-autotemcel, exa-cel), the first-ever CRISPR gene-edited medicine approved in the US.
Key Takeaways
-
Vertex/CRISPR’s Casgevy and bluebird’s Lyfgenia were approved in the US to treat sickle cell disease, the first potentially curative treatments for SCD.
Both therapies’ approvals – for SCD patients aged 12 and older with recurrent vaso-occlusive crises (VOCs) or a history of...
